Outbreaks appear to be exacerbated during childhood and adolescence is less than 200 worldwide, however, many are concerned about the availability and availability of drugs and vaccines for this disease. But drugs and vaccines are available, the Health Policy professor says reassuringly. Elias Mosialos, School of Economics and Political Science (LSE) and Imperial College London.
He points out that “in Hellas, so far, there is no case. Let us remember that neither stigma, nor panic, nor trembling helps. Let’s stay informed and be careful».
He points out that there are treatment options, such as the antiviral tecovirimat (which is approved for the treatment of smallpox in adults and children) and brincidofovir and cidofovir (which could also be effective as they have been shown to be effective against smallpox in laboratory studies and in animal studies).
In the US, 2 million doses of tecovirimat are stored (in the US Strategic National Reserve) in the event of a bioterrorist attack that could cause orthodox virus-related diseases. Canada has also secured installments and many European countries have approached the company that produces it.
There is also, he adds, the possibility of intravenous use of vaccinia immunoglobulin (VIG), i.e. antibodies developed by individuals in response to the smallpox vaccine isolated from their blood and given to patients.
With regard to vaccination, he emphasizes that there is a vaccine to protect against aphids in monkeys in adults., whose efficiency is estimated at 85%. Vaccination is effective even after exposure to monkey pox virus. However, the sooner an exposed person gets the vaccine, the better. US and British health authorities (CDC and UKHSA) recommend that the vaccine be given within four days of exposure to prevent the onset of the disease. If given between 4-14 days after exposure, the vaccine reduces the symptoms, but usually can not prevent the disease.
The vaccine (MVA-BN) was also approved for use in the European Union in 2013 under the name Imvanex, for active immunization against smallpox in adults. Available in the US as JYNNEOS and received since September 2019 FDA approval for the prevention of smallpox and monkeys. However, this vaccine will be available in 2023 and the US Biomedical Advanced Research and Development Authority has already secured 13 million doses. Something similar, as he states, should be done immediately by the European Union through the European Authority for Emergency Preparedness and Response to Health.
Mr. Mosialos concludes that, as with the coronavirus, the pace of updating the available data from the countries where cases have been recorded remains impressive. For example, some countries have already analyzed the genetic material from patient samples and submitted the results to electronic databases, thus contributing to the effort to find the transmission chain..
Follow Skai.gr on Google News
and be the first to know all the news
